Abstract
Background Parkinson’s disease (PD) is characterized by α-synuclein aggregation and loss of dopamine (DA) neurons in the substantia nigra. Risk of PD arises due to a combination of genetic and environmental factors, which may interact, termed gene-environment (GxE) interactions. An inverse association between smoking and risk of PD is well-established, and a previous genome-wide GxE interaction study identified genetic variation in the synaptic-vesicle glycoprotein 2C (SV2C) locus as an important mediator of the degree to which smoking is inversely associated with PD.
Objective We sought to determine the mechanism of the smoking-SV2C interaction in a Drosophila model of PD.
Methods Flies expressing human α-synuclein in all neurons develop the hallmarks of PD, including motor dysfunction, loss of DA neurons, and formation of α-synuclein inclusions. We assessed the effects of increasing doses of nicotine on these parameters of neurodegeneration, in the presence or absence of SV2 knockdown.
Results α-synuclein-expressing flies treated with nicotine had improvement in locomotion, DA neuron counts, and in α-synuclein aggregation. However, in α-synuclein-expressing flies in which Drosophila orthologs of SV2 were knocked down, nicotine failed to rescue neurodegeneration.
Conclusions This work confirms a GxE interaction between nicotine and SV2, defines a role for this interaction in α-synuclein proteostasis, and suggests that future clinical trials on nicotine should consider genetic variation in SV2C. Further, this provides proof of concept that our model can be used for mechanistic study of GxE, paving the way for investigation of additional GxE interactions or identification of novel GxE.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
Financial Disclosures/COI concerning the current manuscript, None
Funding Sources, This work was funded by 1R21 NS0105151 (MBF), 1R01 NS098821 (MBF), 5K08-K08NS109344-03 (ALO), and W81XWH-18-1-0395 (ALO). The study is funded by the joint efforts of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and the Aligning Science Across Parkinson’s (ASAP) initiative. MJFF administers the grant [ASAP-000301] on behalf of ASAP and itself.